X
Xavier Llor
Researcher at Yale University
Publications - 111
Citations - 5471
Xavier Llor is an academic researcher from Yale University. The author has contributed to research in topics: Lynch syndrome & Colorectal cancer. The author has an hindex of 35, co-authored 102 publications receiving 4632 citations. Previous affiliations of Xavier Llor include University of Illinois at Chicago & Autonomous University of Barcelona.
Papers
More filters
Journal ArticleDOI
Accuracy of Revised Bethesda Guidelines, Microsatellite Instability, and Immunohistochemistry for the Identification of Patients With Hereditary Nonpolyposis Colorectal Cancer
Virginia Piñol,Antoni Castells,Montserrat Andreu,Sergi Castellví-Bel,Cristina Alenda,Xavier Llor,Rosa M. Xicola,Francisco Rodríguez-Moranta,Artemio Payá,Rodrigo Jover,Xavier Bessa +10 more
TL;DR: The revised Bethesda guidelines constitute a useful approach to identify patients at risk for HNPCC in patients fulfilling these criteria, and both microsatellite instability testing and immunostaining are equivalent and highly effective strategies to further select those patients who should be tested for MSH2/MLH1 germline mutations.
Journal ArticleDOI
Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer
Rodrigo Jover,Pedro Zapater,Antoni Castells,Xavier Llor,Montserrat Andreu,Joaquín Cubiella,Virginia Piñol,Rosa M. Xicola,Luis Bujanda,Josep Maria Reñe,Juan Clofent,Xavier Bessa,Juan Diego Morillas,David Nicolás-Pérez,Artemio Payá,Cristina Alenda +15 more
TL;DR: Benefit from 5-FU adjuvant chemotherapy depends on the MMR status of tumours in patients with colorectal cancer but this benefit from chemotherapy cannot be extended to patients with MMR deficient tumours.
Journal ArticleDOI
Genetic/Familial high-risk assessment: Colorectal, version 2.2019 featured updates to the NCCN guidelines
Samir Gupta,Dawn Provenzale,Xavier Llor,Amy L. Halverson,William Grady,Daniel C. Chung,Sigurdis Haraldsdottir,Arnold J. Markowitz,Thomas P. Slavin,Heather Hampel,Reid M. Ness,Jennifer M. Weiss,Dennis J. Ahnen,Lee-may Chen,Gregory S. Cooper,Dayna S. Early,Francis M. Giardiello,Michael J. Hall,Stanley R. Hamilton,Priyanka Kanth,Jason B. Klapman,Audrey J. Lazenby,Patrick M. Lynch,Robert J. Mayer,June Mikkelson,Shajan Peter,Scott E. Regenbogen,Mary A. Dwyer,Ndiya Ogba +28 more
TL;DR: The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Colorectal provide recommendations for the assessment and management of patients with high-risk colon cancer syndromes as discussed by the authors.
Journal ArticleDOI
Risk of cancer in cases of suspected lynch syndrome without germline mutation.
María Rodríguez Soler,Lucía Pérez–Carbonell,Carla Guarinos,Pedro Zapater,Adela Castillejo,Víctor Manuel Barberá,Miriam Juárez,Xavier Bessa,Rosa M. Xicola,Juan Clofent,Luis Bujanda,Francesc Balaguer,Josep Maria Reñe,Luísa Castro,José Carlos Marín Gabriel,Angel Lanas,Joaquín Cubiella,David Nicolás Pérez,Alejandro Brea–Fernández,Sergi Castellví–Bel,Cristina Alenda,Clara Ruiz–Ponte,Angel Carracedo,Antoni Castells,Montserrat Andreu,Xavier Llor,José Luis Soto,Artemio Payá,Rodrigo Jover +28 more
TL;DR: The risk of cancer in families of patients with LLS is lower that of families with Lynch syndrome but higher than that offamilies with sporadic CRC, confirming the need for special screening and surveillance strategies for these patients and their relatives.
Journal ArticleDOI
The efficacy of adjuvant chemotherapy with 5-fluorouracil in colorectal cancer depends on the mismatch repair status.
Rodrigo Jover,Pedro Zapater,Antoni Castells,Xavier Llor,Xavier Llor,Montserrat Andreu,Joaquín Cubiella,Francesc Balaguer,Laura Sempere,Rosa M. Xicola,Rosa M. Xicola,Luis Bujanda,Josep Maria Reñe,Juan Clofent,Xavier Bessa,Juan Diego Morillas,David Nicolás-Pérez,Elisenda Pons,Artemio Payá,Cristina Alenda +19 more
TL;DR: In a cohort of colorectal cancer patients, those with MMR-deficient tumours seem not to benefit from 5-FU-based chemotherapy.